Gamida Cell Ltd. (NASDAQ:GMDA) has scheduled a conference call for 10th November 2020 at 8:30 AM Eastern Time to announce its 3Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.gamida-cell.com
Earnings Expectation
Gamida Cell Ltd. is reporting third quarter financial results on Tuesday 10th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, GMDA is expected to report 3Q20 loss of $ 0.31 per share. For the full year, analysts anticipate top line of $ 0.14 million, while looking forward to loss of $ 1.37 per share bottom line.
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The companys lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma.
